Detail of "171500-79-1"

Reference

Infections associated with orthopedic implants

All Rights Reserved. Infections associated with orthopedic implants. Trampuz, Andrej; Widmer, Andreas F. (Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switz.). Current Opinion in Infectious Diseases, 19(4), 349-356 (English) 2006 Lippincott Williams & Wilkins. CODEN: COIDE5. ISSN: 0951-7375. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Purpose of review: We review recent advances in the prevention, diagnosis and treatment of infections assocd. with joint prostheses and internal fixation devices. Recent findings: The perioperative antimicrobial prophylaxis should be administered 60-30 min before incision or before inflation of the tourniquet. New diagnostic approaches include sonication of removed implants to dislodge adherent microorganisms growing in biofilms and the use of mol. techniques to improve diagnostic yield. Treatment of implant-assocd. infections without removal of the device is an established option for selected patients. Treatment with rifampin combinations in staphylococcal infections is crucial for success. 171500-79-1 and 220620-09-7 are also in the experiment. As demonstrated in vitro, in animal studies and in clin. trials, quinolones are suitable combination agents with rifampin against susceptible staphylococci, but increasing antimicrobial resistance requires evaluation of alternative combination agents, such as quinupristin-dalfopristin, linezolid, and daptomycin, although clin. experience is limited. New antimicrobial agents, such as dalbavancin, tigecycline, iclaprim, and novel rifamycin derivs. are studied. Summary: Better understanding of the interaction between microorganisms, the implant and the host may improve our current approach to the diagnosis and treatment of implant-assocd. infections. The treatment modality depends on duration of infection, stability of the implant, antimicrobial susceptibility of the pathogen and condition of the surrounding soft tissue. .

Dalbavancin compositions for treatment of bacterial infections

Dalbavancin compositions for treatment of bacterial infections.Some chemicals with cas registry numbers like 63-42-3 and 171500-79-1 are also used. Stogniew, Martin (Vicuron Pharmaceuticals, Inc., USA). U.S. Pat. Appl. Publ. US 2005004050 A1 6 Jan 2005, 55 pp., Cont.-in-part of U.S. Ser. No. 714,261. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-704. APPLICATION: US 2004-834395 27 Apr 2004. PRIORITY: US 2002-2002/PV42765U 18 Nov 2002; US 2003-2003/PV48569U 8 Jul 2003; US 2003-2003/PV49504U 13 Aug 2003; US 2003-2003/PV49648U 19 Aug 2003; US 2003-2003/714261 14 Nov 2003. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 16 The invention provides methods and compns. for treatment of bacterial infections. A dosage form comprises a sterile, stable, particle-free dalbavancin powder and a stabilizer, i.e., mannitol and/or lactose, wherein the dosage form degrades by no more than about 2% at about 40° after about 3 mo. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-pos. bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the blood stream for at least one week, providing prolonged therapeutic action against a bacterial infection. For example, a single 1000 mg i.v. dose of dalbavancin was well-tolerated in healthy subjects. Following a single i.v. infusion of 1000 mg, plasma concns. of dalbavancin above 45 mg/L were maintained for at least 7 days, which is above concns. known to be bactericidal (4-32 mg/L). This supports the use of dalbavancin as a once-weekly regimen. The urinary elimination profile indicates that renal excretion is an important elimination pathway, with approx. 40% excreted in urine. Since the kidneys are not the exclusive elimination route, a dosing adjustment for dalbavancin may not be necessary in renally impaired patients. Also, dalbavancin given as an initial i.v. dose of 1000 mg followed 1 wk later by a second i.v. dose of 500 mg appears well tolerated and highly effective for the treatment of catheter-related blood stream infection caused by Gram-pos. pathogens, with superior response rates to vancomycin. .